Kane Biotech Inc.
KNE.V
TSX
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 219.69% | -90.44% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 219.69% | -90.44% | |||
| Cost of Revenue | 69.45% | -71.33% | |||
| Gross Profit | 147.51% | -115.21% | |||
| SG&A Expenses | 181.97% | -67.81% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 63.06% | -51.58% | |||
| Operating Income | -38.88% | -29.96% | |||
| Income Before Tax | -9.75% | -55.47% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -622.78% | 132.64% | |||
| Earnings from Discontinued Operations | -- | -1,852.81% | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -9.75% | -74.16% | |||
| EBIT | -38.88% | -29.96% | |||
| EBITDA | -42.58% | -34.96% | |||
| EPS Basic | -1.79% | -69.70% | |||
| Normalized Basic EPS | -25.00% | -21.74% | |||
| EPS Diluted | -1.79% | 18.84% | |||
| Normalized Diluted EPS | -25.00% | -21.74% | |||
| Average Basic Shares Outstanding | 9.04% | 2.86% | |||
| Average Diluted Shares Outstanding | 9.04% | 2.86% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||